Page 4 - பட்ஜெட் தாக்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  relapsed or refractory chronic lymphocytic leukaemia   progression after 12 months vs. 68% for comparators   AstraZeneca s Calquence (acalabrutinib), a next-generation, selective Bruton s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]).   The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I trial in Japanese patients, showing Calquence monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus a standard treatment of rituximab, a monoclonal antibody, combined with the physician s choice of idelalisib, a PI3-kinase inhibitor or bendamustine, a chemotherapy.

Dai maruyamaJapan generalUnited statesUnited kingdomDave fredricksonAcerta pharmaRituximab idAstrazeneca calquenceAcalabrutinib acalaAdrian kempNational cancer instituteAmerican society of clinical oncologyNational cancer institute information serviceEuropean hematology associationVirtual edition of the european hematology associationCompany on twitter astrazeneca